Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.45 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.37 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.35 |
| ▸ | TK1 | P04183 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082848 | 0.88 | DUT (0.37) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL1009599 | 0.87 | DUT (0.45) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL6035974 | 0.87 | DUT (0.47) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL3072374 | 0.87 | DUT (0.37) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15414026 | 0.85 | DUT (0.46) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL7394361 | 0.85 | DUT (0.42) | DUTP2RY2P2RY6P2RY4 | |
| SCHEMBL986334 | 0.83 | DUT (0.52) | DUTP2RY2P2RY6P2RY4 | |
| SCHEMBL3340603 | 0.83 | DUT (0.50) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL4201158 | 0.83 | DUT (0.50) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL2557435 | 0.83 | DUT (0.50) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 666 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367301-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TRIPLE-NEGATIVE BREAST CANCER, COMPRISING OLIGONUCLEOTIDE AS ACTIVE INGREDIENT | INTEROLIGO CORPORATION (KR) | 2025-12-04 | — | — | US | claimed |
| US-12448624-B2 | Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same | INTEROLIGO CORPORATION (KR) | 2025-10-21 | — | — | US | claimed |
| CN-112888700-B | Modified nucleic acid having improved therapeutic efficacy and anticancer pharmaceutical composition containing the same | 因特欧力多公司 | 2025-03-04 | — | — | CN | claimed |
| US-20250049927-A1 | MODIFIED OLIGONUCLEOTIDE-DRUG CONJUGATE AND USE THEREOF | INTEROLIGO CORPORATION. (KR) | 2025-02-13 | — | — | US | claimed |
| EP-4450092-A1 | MODIFIED OLIGONUCLEOTIDE-DRUG CONJUGATE AND USE THEREOF | Interoligo Corporation (KR) | 2024-10-23 | — | — | EP | claimed |
| US-20240270780-A1 | PROTEOLYSIS TARGETING COMPOUND WITH TISSUE TARGETING CAPABILITY AND USE THEREOF | TAI BI DI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2024-08-15 | — | — | US | claimed |
| CN-118382461-A | Modified oligonucleotide-drug conjugates and uses thereof | 因特欧力多公司 | 2024-07-23 | — | — | CN | claimed |
| EP-4382134-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TRIPLE-NEGATIVE BREAST CANCER, COMPRISING OLIGONUCLEOTIDE AS ACTIVE INGREDIENT | Interoligo Corporation. (KR) | 2024-06-12 | — | — | EP | claimed |
| CN-117835987-A | Pharmaceutical composition for preventing or treating triple negative breast cancer containing oligonucleotide as active ingredient | 因特欧力多公司 | 2024-04-05 | — | — | CN | claimed |
| WO-2023113243-A1 | MODIFIED OLIGONUCLEOTIDE-DRUG CONJUGATE AND USE THEREOF | 인터올리고 주식회사 | 2023-06-22 | — | — | WO | claimed |
| CN-1082894-A | The anti-viral pharmaceutical compositions of vagina administration | L C PHARCHEM LTD (CY) | 1994-03-02 | — | — | CN | claimed |
| WO-1993023094-A1 | USE OF HYDROGELS TO FIX BONE REPLACEMENTS | M.U.R.S.T., ITALIAN MINISTRY FOR UNIVERSITIES AND SCIENTIFIC AND TECHNOLOGICAL RESEARCH (IT) | 1993-11-25 | — | — | WO | claimed |
| WO-1993018763-A1 | COMPOSITIONS OF N-(PHOSPHONOACETYL)-L-ASPARTIC ACID AND METHODS OF THEIR USE AS BROAD SPECTRUM ANTIVIRALS | U.S. BIOSCIENCE, INC. (US) | 1993-09-30 | — | — | WO | claimed |
| WO-1993002662-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITIONS FOR VAGINAL ADMINISTRATION | L.C. PHARCHEM LTD. (CY) | 1993-02-18 | — | — | WO | claimed |
| EP-0226029-B1 | THYMIDINE KINASE DELETION MUTANTS OF BOVINE HERPESVIRUS-1, VACCINES AGAINST INFECTIOUS BOVINE RHINOTRACHEITIS CONTAINING SAME AND METHODS FOR THE PRODUCTION AND USE OF THE SAME | NOVAGENE, INC. (US) | 1992-03-11 | — | — | EP | claimed |
| US-4902678-A | SYNERGISTIC MIXTURE; HERPES VIRUS INFECTIONS | SYNTEX (U.S.A.) INC. (US) | 1990-02-20 | — | — | US | claimed |
| EP-0101441-B1 | ANTI-VIRAL COMPOSITIONS | SYNTEX (U.S.A.) INC. (US) | 1987-01-14 | — | — | EP | claimed |
| EP-0101441-A4 | ANTI-VIRAL COMPOSITIONS. | ENS BIO LOGICALS INC (CA) | 1985-04-11 | — | — | EP | claimed |
| EP-0101441-A1 | ANTI-VIRAL COMPOSITIONS. | ENS BIO LOGICALS INC (CA) | 1984-02-29 | — | — | EP | claimed |
| WO-1983002723-A1 | ANTI-VIRAL COMPOSITIONS | SMITH, KENDALL, O. | 1983-08-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270780-A1 | PROTEOLYSIS TARGETING COMPOUND WITH TISSUE TARGETING CAPABILITY AND USE THEREOF | ASGR1, ADRM1, PSMB11 | DUT 3747/4885SLC28A1 3255/4885SLC28A2 3237/4885 |
| US-20250367301-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TRIPLE-NEGATIVE BREAST CANCER, COMPRISING OLIGONUCLEOTIDE AS ACTIVE INGREDIENT | BRCA1, POLN, POLRMT | DUT 46/4885SLC28A1 853/4885SLC28A2 1003/4885 |
| US-20250049927-A1 | MODIFIED OLIGONUCLEOTIDE-DRUG CONJUGATE AND USE THEREOF | DCLRE1B, DUT, DCTD | DUT 2/4885SLC28A1 224/4885SLC28A2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.